Article
Successful Treatment with Modified FOLFOX6 and Panitumumab in a Cecal Cancer Patient Undergoing Hemodialysis.
Internal medicine (Tokyo, Japan) - 1 Jan 2016
Kobayashi Mariko, Endo Shinji, Hamano Yukako, Imanishi Mamiko, Akutsu Daisuke, Sugaya Akinori, Ochi Daisuke, Moriwaki Toshikazu, Hyodo Ichinosuke
Abstract excerpt
Combination chemotherapy of mFOLFOX6 (5-fluorouracil, leucovorin, and oxaliplatin) plus panitumumab, a fully human monoclonal antibody against epidermal growth factor receptor (EGFR), is one of the standard treatments for metastatic colorectal cancer (mCRC) without KRAS mutation. A few reports suggested no need of dose adjustment of cetuximab, a similar chimeric anti-EGFR antibody, in patients with renal...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.